Vaccine Cold Chain Market Size, Share & Forecast 2026-2032
Vaccine cold chain at $37.78B in 2026 reaching $56.8B by 2032 at 7.03% CAGR. Published 2025 sizings span 11.2x; UNICEF's 2.787bn doses test every one of them.
$37.8B
$56.8B
7.03%
Global
Executive Summary
Vaccine cold chain is the worst-measured market in this corpus. Published 2025 sizings run from $4.13 billion to a derived $46.35 billion, an 11.2x spread, and stated growth rates from 0.85% to 10.23%, a 12.0x spread in the rate - extreme on both dimensions at once. One publisher disagrees with itself: IMARC prints vaccine storage and packaging at $35.3 billion growing at 7.03% and healthcare cold chain logistics at $18.1 billion growing at 2.8%. The buyer side settles more than the supplier side can. UNICEF, the largest single vaccine buyer in the world, delivered 2.787 billion doses to 99 countries in 2024 and spent $5.610 billion on all procurement across 160 countries, supplies and services and vaccines included. The derived $46.35 billion vaccine cold chain is therefore 8.26 times UNICEF's entire budget, and IMARC's $35.3 billion is 6.29 times it. Dividing each published market by UNICEF's dose volume gives $1.48, $12.67 and $16.63 of cold chain cost per dose; even assuming a global volume of 6 billion doses the larger two still imply $5.88 and $7.73, against routine antigen prices measured in cents to a few dollars. Only the logistics-only figure is plausible as the cost of moving a dose. We publish IMARC's storage-and-packaging series, which is the most completely disclosed scope in the set, rebased to 2026 at its own stated rate - and we publish the stated rate rather than the stated endpoint, because 35.3 x 1.0703^9 = 65.01 against a published 66.3 billion.
Key Highlights
Published 2025 sizings span 11.2x ($4.13 billion to a derived $46.35 billion) and stated growth rates span 12.0x (0.85% to 10.23%) - extreme disagreement on both dimensions at once
UNICEF delivered 2.787 billion vaccine doses to 99 countries in 2024 on total procurement of $5.610 billion, which makes the derived $46.35 billion vaccine cold chain 8.26 times the entire budget of the world's largest vaccine buyer
Dividing the published markets by UNICEF's dose volume gives $1.48, $12.67 and $16.63 per dose; only the first is plausible as the cost of moving and storing a routine immunisation dose
IMARC's series fails its own arithmetic: 35.3 x 1.0703^9 = 65.01 against a published $66.3 billion endpoint, which implies 7.26% rather than the stated 7.03%
The sector's only listed pure-play, Cryoport, had total 2025 revenue of $176.2 million - 4.3% of even the smaller published market - and its growth came from cell and gene therapy, not vaccines
WHO's prequalified immunization device catalogue cannot be used as a count: its own guidance states references are never reassigned, so retired products leave permanent gaps in the numbering
Market Overview
Market Context
Vaccine cold chain is a cost centre inside a system funded by donors and ministries of health, not a market with a price-setting mechanism of its own. UNICEF, Gavi and PAHO buy most of the doses that move through it, publish awarded prices per antigen, and tender the logistics; the result is that the ceiling on cold chain spend per dose is set by what a public immunisation budget can bear, not by what the service is worth. That is why the growth rates in this sector have diverged so sharply from the rest of healthcare logistics. The money in temperature-controlled life science supply has moved to cell and gene therapy, where a single shipment can be worth more than a million doses of measles vaccine - Cryoport's commercial cell and gene therapy revenue grew 29% in 2025 while the vaccine-specific logistics market is forecast at under 1% a year. The ultra-cold capacity built for mRNA COVID vaccines is now serving that higher-value traffic. Vaccine cold chain inherits the installed base and keeps the volume, but not the pricing power.
Vaccine cold chain carries the widest published disagreement in this corpus on both dimensions at once. For 2025 the estimates run from $4.13 billion to a derived $46.35 billion, an 11.2x spread, and the stated growth rates run from 0.85% to 10.23%, a 12.0x spread in the rate itself. One publisher disagrees with itself by almost two to one. UNICEF settles part of it: it delivered 2.787 billion vaccine doses to 99 countries in 2024 and spent $5.610 billion on all procurement across 160 countries, so a $46.35 billion vaccine cold chain is 8.26 times the entire budget of the world's largest vaccine buyer, including the vaccines. Dividing the published markets by UNICEF's dose volume gives $1.48, $12.67 and $16.63 per dose. Only the first is plausible as the cost of moving a dose; the larger figures are defensible only as equipment plus packaging plus services, which is what the publisher we follow says it counts.
Market Stage
Mature
Adoption Level
Universal and mandatory for licensed vaccines; the constraint is last-mile equipment and monitoring in low-income settings
Key Trends
Market Forecast & Data
Base Year (2026)
$37.8B
Forecast (2032)
$56.8B
CAGR (2026-2032)
7.03%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $37.78B |
| 2027 | $40.44B |
| 2028 | $43.28B |
| 2029 | $46.33B |
| 2030 | $49.59B |
| 2031 | $53.08B |
| 2032 | $56.80B |
We publish 7.03%, which is IMARC's own stated rate for its vaccine storage and packaging scope, and we deliberately prefer the rate to the publisher's own endpoint because the two do not reconcile: 35.3 x 1.0703^9 gives $65.01 billion against a published $66.3 billion for 2034, an implied 7.26%. Advancing the 2025 base one year gives 35.3 x 1.0703 = $37.78 billion for 2026, and interpolating on the same rate gives 37.78 x 1.0703^6 = $56.80 billion for 2032, inside the publisher's series rather than at its endpoint. The 7.03% rate sits between the two bounding readings for a defensible reason. The 0.85% logistics-only rate reflects COVID normalisation in a service consumed once per dose; the 10.23% whole-healthcare rate reflects cell and gene therapy growth that has nothing to do with vaccines. An equipment-weighted vaccine market should grow faster than the first, because installed hardware generates replacement demand on a service-life cycle independent of dose volumes, and slower than the second, because none of the high-value cell and gene traffic is in its scope. What the rate does not price is whether donor immunisation budgets grow at all, which is the actual determinant and is political.
Market Dynamics
- Routine immunisation volume is enormous and non-discretionary: UNICEF alone delivered 2.787 billion doses to 99 countries in 2024, stated as enough to reach 45% of the world's children under five
- Ultra-cold and cryogenic capability built for mRNA COVID vaccines is now installed capacity that serves cell and gene therapy and clinical trial logistics, which is where Cryoport's growth came from in 2025
- Equipment replacement rather than new installation drives the hardware half of the market: a prequalified vaccine refrigerator has a defined service life, so a large installed base generates recurring demand independent of dose growth
- Temperature monitoring and data logging have shifted from optional to expected, adding a per-shipment software and device cost that did not exist a decade ago
- Solar direct-drive refrigeration has made cold chain viable in settings without reliable grid power, expanding the equipment market into locations that previously could not hold a vaccine at all
Market Segmentation
By Type
- Storage Equipment (Refrigerators, Freezers, Cold Rooms)
- Passive Packaging (Cool Bags, Cold Boxes, Vaccine Carriers)
- Transportation Services (Ground, Air, Ocean)
- Warehouse Storage Services
- Temperature Monitoring and Data Logging
By End User
- UN Agencies and Donor-Funded Immunisation Programmes
- National Immunisation Programmes and Ministries of Health
- Biopharmaceutical Manufacturers
- Hospitals and Primary Care Facilities
- Medical Laboratories
By Application
- Routine Childhood Immunisation
- Outbreak and Campaign Response
- Adult and Seasonal Influenza Vaccination
- Clinical Trial Vaccine Supply
Competitive Landscape
Cryoport
Brentwood, Tennessee, United States
Reports both halves of the business: Life Sciences Services at $96.497 million, up 17.6%, and Life Sciences Products at $79.680 million, up 6.6%, for FY2025. Growth came from cell and gene therapy rather than vaccines - commercial cell and gene therapy support rose 29% to a record $33.4 million and clinical trial support 14% to $47.1 million. Gross margin improved from 44.4% to 47.1% and the company guided to $190-194 million for 2026. Entered a strategic partnership with DHL Group that included DHL acquiring CRYOPDP.
Thermo Fisher Scientific
Waltham, Massachusetts, United States
The largest supplier of the hardware half of this market by breadth, spanning pharmacy refrigerators, ultra-low temperature freezers built out during the mRNA COVID campaign, and cryogenic storage. Because the equipment is sold into laboratory, clinical, biobanking and vaccine applications from a single catalogue and reported inside wider segments, no vaccine-specific figure is derivable from its filings.
DHL Group (Life Sciences & Healthcare)
Bonn, Germany
Operates the global air and ground freight and certified pharmaceutical warehousing on which donor-funded vaccine delivery depends. Reinforced its position in the specialist end of the market through a strategic partnership with Cryoport and the acquisition of CRYOPDP, which consolidated one of the few remaining independent specialist couriers in the sector.
Kuehne+Nagel
Schindellegi, Switzerland
Competes with DHL for the lane management, airport-to-airport and bonded storage work that moves bulk vaccine consignments between manufacturer and country. Its disclosure, like DHL's, aggregates healthcare logistics into a wider division, which is the structural reason this market has no supply-side sum to test published sizings against.
Envirotainer
Rosersberg, Sweden
Occupies the active-container segment that Roots Analysis separates from passive packaging. An active container holds temperature electronically through a long-haul flight and is leased rather than sold, which makes its economics per shipment rather than per unit - the clearest case in this market of a cost that scales with doses moved rather than with installed base.
B Medical Systems
Hosingen, Luxembourg
Sells into the UN and donor procurement channel that requires listing in the WHO Catalogue of Prequalified Immunization Devices, where refrigerators and freezers sit in category E003. Prequalification is the commercial moat in this segment: a product in the catalogue is procurable by UN agencies and one without it is not, regardless of its specifications.
Recent Developments
Reported fourth-quarter and full-year 2025 results on 3 March 2026: revenue of $176.2 million, above the high end of guidance and up about 12%, with Life Sciences Services at $96.497 million (+17.6%) and Life Sciences Products at $79.680 million (+6.6%); commercial cell and gene therapy support rose 29% to a record $33.4 million; gross margin improved to 47.1% from 44.4%; 2026 guidance of $190-194 million.
Published a vaccine storage and packaging market of $35.3 billion for 2025 rising to $66.3 billion by 2034 at a stated 7.03% CAGR on 15 May 2026 - a series whose stated rate and stated endpoint do not reconcile, since 35.3 x 1.0703^9 gives 65.01 and the endpoint implies 7.26%.
Updated its Cold Chain Logistics Market for Vaccines report in August 2026 with a 2025 value of $4.13 billion growing at 0.85% a year to $4.32 billion by 2030, segmented explicitly by COVID-19 versus other vaccines - the lowest growth rate published for any market in this corpus.
Entered a strategic partnership with Cryoport that included DHL's acquisition of CRYOPDP, consolidating one of the few remaining independent specialist temperature-controlled couriers into a global logistics network.
Delivered 2.787 billion vaccine doses to 99 countries, stated as enough to reach 45% of the world's children under five, on total procurement of $5.610 billion across 160 countries - $3.778 billion of supplies and $1.832 billion of services, a 7% increase on the previous year.
Regulatory Landscape
Research Methodology
Primary research
- Division of each published market size by UNICEF's disclosed 2024 vaccine dose volume to derive an implied cold chain cost per dose, and comparison of each against UNICEF's total procurement budget
- Derivation of a vaccine slice of the healthcare cold chain by multiplying one publisher's whole-market total by its own stated vaccine product share, labelled as derived and used only to bound the spread
Secondary research
- UNICEF Supply Annual Report 2024 - 2.787 billion vaccine doses delivered to 99 countries, enough to reach 45% of the world's children under five; total 2024 procurement $5.610 billion across 160 countries, of which $3.778 billion supplies and $1.832 billion services
- Cryoport, Inc. Fourth Quarter and Full-Year 2025 Financial Results, 3 March 2026 - revenue $176.2 million, Life Sciences Services $96.497 million (+17.6%), Life Sciences Products $79.680 million (+6.6%), commercial cell and gene therapy support $33.4 million (+29%), gross margin 47.1%
- IMARC Group, Global Vaccine Storage and Packaging Market, published 15 May 2026 - $35.3 billion (2025) to $66.3 billion (2034) at a stated 7.03% CAGR for 2026-2034, historical period 2020-2025, with disclosed equipment, packaging-type and packaging-level segmentation
- Roots Analysis, Cold Chain Logistics Market for Vaccines: Industry Trends and Global Forecasts till 2030, last updated August 2026 - $4.13 billion (2025), $4.18 billion (2026) to $4.32 billion (2030) at 0.85%, segmented by COVID-19 versus other vaccines
- Mordor Intelligence, Healthcare Cold Chain Market, page updated 11 September 2026 with estimates as of January 2026 - $124.53 billion (2025) to $223.39 billion (2031) at 10.23%, with vaccines stated at 37.23% of 2025 market revenue
- WHO Catalogue of Prequalified Immunization Devices (IMD-PQS), refrigerators and freezers in category E003, edition dated 14 February 2025, including the guidance that product references are never reassigned so gaps appear in the sequence
- IMARC Group, Global Healthcare Cold Chain Logistics Market Report and Forecast 2025-2033 - $18.1 billion (2024) to $23.2 billion (2033) at 2.8%, the same publisher's logistics-only scope
Validation: Three tests were run against countable public figures rather than against another forecast. First, each published market size was divided by UNICEF's disclosed 2024 vaccine delivery volume of 2.787 billion doses, giving an implied cold chain cost per dose of $1.48 for Roots Analysis' logistics-only figure, $12.67 for IMARC's storage-and-packaging figure and $16.63 for the vaccine slice derived from Mordor's whole-market total. Allowing a generous global dose volume of 6 billion, more than double UNICEF's, the latter two still imply $5.88 and $7.73 per dose. Second, and decisively, the derived $46.35 billion vaccine cold chain figure was compared with UNICEF's total 2024 procurement of $5.610 billion, which covered all supplies and all services for 160 countries including the vaccines themselves: the derived market is 8.26 times that budget and IMARC's figure 6.29 times it. Third, the only listed pure-play in the sector, Cryoport, reported total 2025 revenue of $176.2 million, which is 4.3% of the smaller published market and 0.38% of the larger, with its growth coming from cell and gene therapy rather than vaccines - corroborating the COVID-normalisation reading behind the 0.85% logistics rate. These are plausibility tests, not market estimates. They rule the logistics-only reading in as a measure of moving doses and establish that the larger figures are defensible only as equipment plus packaging plus services, which is what the publisher we follow discloses that it counts. The $46.35 billion figure is our own multiplication of a whole-market total by a stated product share and is not a published number. Separately, IMARC's own series fails its own arithmetic: 35.3 x 1.0703^9 = 65.01 against a published 66.3 billion, and the endpoint implies 7.26% against a stated 7.03%, so we publish the stated rate and not the stated endpoint.
Strategic Takeaways
equipment plus packaging plus services is roughly 8.5x the logistics-only reading, and the two are published under names a reader cannot distinguish
UNICEF's annual report is the most useful document in this market - 2.787 billion doses and $5.610 billion of total procurement for 2024 - because it converts any market size claim into a cost per dose you can sanity-check
A cold chain cost above a few dollars per dose should be rejected on its face for routine immunisation, since the vaccine inside the box is itself priced in cents to a few dollars
Cryoport's 2025 growth came from a 29% rise in commercial cell and gene therapy support
When a publisher's stated CAGR and stated endpoint disagree, as IMARC's do by 0.23 points here, prefer the rate and say so - the endpoint is usually the rounded model output
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- PharmaceuticalsPlasma Fractionation Market$39.5B · 7.6% CAGR
- PharmaceuticalsSterile Injectables Market$51.3B · 10.5% CAGR
- PharmaceuticalsOphthalmic Therapeutics Market$51.4B · 4.26% CAGR
- PharmaceuticalsGlobal Biosimilars Market$26.5B · 14.5% CAGR
- PharmaceuticalsBiologics CDMO Market$20.9B · 11% CAGR
- PharmaceuticalsGLP-1 Receptor Agonists Market$71.9B · 12.1% CAGR